Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.23
-0.18 (-1.91%)
At close: Aug 20, 2026, 4:00 PM EDT
9.24
+0.01 (0.11%)
After-hours: Aug 20, 2026, 4:53 PM EDT
Xilio Therapeutics Revenue
Xilio Therapeutics had revenue of $18.69M in the quarter ending June 30, 2026, with 131.22% growth. This brings the company's revenue in the last twelve months to $64.09M, up 327.25% year-over-year. In the year 2025, Xilio Therapeutics had annual revenue of $43.77M with 589.88% growth.
Revenue (ttm)
$64.09M
Revenue Growth
+327.25%
P/S Ratio
0.95
Revenue / Employee
$843,316
Employees
76
Market Cap
60.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 43.77M | 37.42M | 589.88% |
| Dec 31, 2024 | 6.34M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Gossamer Bio | 53.29M |
| MindWalk Holdings | 11.43M |
| MediciNova | 920.48K |
| ImageneBio | 800.00K |
| INmune Bio | 50.00K |
XLO News
- 8 days ago - Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 8 days ago - Xilio Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Xilio Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - TheFly
- 7 weeks ago - Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Registration statement: Registration filing - Filings
- 3 months ago - Xilio Therapeutics files $250M mixed securities shelf - TheFly